Sequences are standardised representations of biological sequences, typically nucleotide (DNA/RNA) or amino acid (protein) sequences, that are included in patent…
Read More
Filter By
Chinese utility model patents: an IP right overlooked by UK businesses?
When UK businesses think of protecting their innovations abroad, China is high on the list. As one of the world’s…
Read More
No appeals without a party: EPO decides interveners cannot continue appeals alone
On 25 September 2025, the EPO’s Enlarged Board of Appeal (‘EBoA’) issued its decision in case G 2/24, the third…
Read More
Intellectual Property on the growth agenda – turning creative assets into commercial advantage
For many SMEs, intellectual property (IP) is treated as a defensive measure – something to protect against theft or infringement….
Read More
The cost of doing nothing – how ignoring Intellectual Property protection can erase years of hard work
When you’ve helped a client build a thriving business, the last thing you want to see is their success unravel,…
Read More
Intellectual Property: the most valuable asset missing from the balance sheet
Why Intellectual Property (IP) deserves a place in every SME’s strategic plan Ask most SME owners to list their most…
Read More
EPO confirms to Barker Brettell that they are making updates to the register to accept colour drawing as well as greyscale when an application is filed electronically from 1 October 2025
According to a recent exchange between Barker Brettell and The European Patent Office (EPO), it is about to modernise its…
Read More
It’s not (just) an album cover, it’s a registerable design
Walk out of any gig or concert and you will likely be welcomed to a ‘black parade’ of counterfeit merchandise….
Read More
Referral to the EPO Enlarged Board on description amendments
Over the past few years, the issue of whether the description of a European patent or application should be amended…
Read More
Patenting antibodies in Europe and beyond: a comparative guide to the IP5
A Briefing Paper Antibodies and their derivatives, including bispecific and multispecific antibodies, fragments, and fusion products, have become central to…
Read More
G 1/23 – See no evil: can the skilled person turn a blind eye to prior art they have in their hand?
The EPO’s Enlarged Board of Appeal (EBA) have issued their decision on G 1/23, providing further clarity to attorneys, patentees and…
Read More
How do I decide whether to opt out of the Unified Patent Court?
The Unified Patent Court (UPC) allows granted European patents to be enforced or challenged centrally and for a single ruling…
Read More